WHITE PAPER
A Perspective on How 2022 Began Defining the New Normal
Apr 21, 2023

The global pharmaceutical market has experienced significant changes since the onset of the COVID-19 pandemic. While there have been positive developments in the use of medicines globally, the volume and launch of innovative drugs has stuttered, and healthcare systems continue to face constraints.

Uneven recovery and stressed healthcare systems mark the post-pandemic pharma environment

In 2022, the global pharmaceutical market witnessed a continuation of the steady increase in the use of medicines as measured by volume (see Figure 1). This increase has primarily been driven by the generics sector due to the cost-containment measures employed by numerous countries. However, the volume of innovative medicines remains below pre-pandemic levels, which is partly due to budget constraints and disrupted care pathways. This raises concerns for the industry's ability to continue introducing innovation into the market at all points in the value chain, from drugs targeting novel pathways to new delivery devices. This decline in volume has also contributed to slower sales than normal. The trajectory sales of innovative launches are shallower after the pandemic for a basket of launches in top developed countries, reaching a gap of -19% on average.

To learn more, fill in your details on the left to download the white paper. If you would like to watch the accompanying webinar, this is now available on demand at the link here.

Related solutions

Contact Us